An experimental Covid-19 vaccine from Pfizer Inc. and BioNTech SE was 95% effective in final results from a pivotal study and is showing signs of being safe, key pieces of data as the companies prepare to ask health regulators to authorize use.
Pfizer plans to seek authorization for the vaccine within days, the companies said Wednesday, leaving the shot on track to go into distribution by the end of the year if health regulators permit.
Out…
This post first appeared on wsj.com
